Novo Nordisk’s dual-hormone combination—semaglutide plus a long-acting amylin analog—and what three Phase III trials reveal about the limits of combination pharmacology

CagriSema represents Novo Nordisk’s strategic response to the competitive pressure created by tirzepatide’s superior weight loss over semaglutide monotherapy. The combination pairs semaglutide—the GLP-1 receptor agonist with the longest clinical track record in obesity—with cagrilintide, a long-acting analog of amylin engineered to match semaglutide’s ~7-day half-life. The pharmacological rationale is that GLP-1 and amylin suppress appetite through distinct neurobiological pathways: GLP-1 primarily reduces appetite and food cravings between meals, while amylin signals meal-time satiety that terminates eating during a meal. Together, they cover both halves of the eating cycle.

The REDEFINE Phase III program has now published three trials—REDEFINE 1 (N=3,417, non-diabetic obesity), REDEFINE 2 (N=1,206, type 2 diabetes), and REDEFINE 4 (N=809, head-to-head versus tirzepatide)—all in major journals. The weight loss data is clinically meaningful: 20.4% at 68 weeks in REDEFINE 1 (intention-to-treat), substantially exceeding semaglutide monotherapy. But the head-to-head story is more complex: REDEFINE 4 failed to demonstrate noninferiority to tirzepatide, a result that rattled Novo Nordisk’s stock price and forced a nuanced conversation about what “close but not equivalent” means for prescribers and patients. This article examines all of it—the mechanism, the data, the competitive context, and the honest gaps.

Novo Nordisk’s dual-hormone combination—semaglutide plus a long-acting amylin analog—and what three Phase III trials reveal about the limits of combination pharmacology

CagriSema represents Novo Nordisk’s strategic response to the competitive pressure created by tirzepatide’s superior weight loss over semaglutide monotherapy. The combination pairs semaglutide—the GLP-1 receptor agonist with the longest clinical track record in obesity—with cagrilintide, a long-acting analog of amylin engineered to match semaglutide’s ~7-day half-life. The pharmacological rationale is that GLP-1 and amylin suppress appetite through distinct neurobiological pathways: GLP-1 primarily reduces appetite and food cravings between meals, while amylin signals meal-time satiety that terminates eating during a meal. Together, they cover both halves of the eating cycle.

The REDEFINE Phase III program has now published three trials—REDEFINE 1 (N=3,417, non-diabetic obesity), REDEFINE 2 (N=1,206, type 2 diabetes), and REDEFINE 4 (N=809, head-to-head versus tirzepatide)—all in major journals. The weight loss data is clinically meaningful: 20.4% at 68 weeks in REDEFINE 1 (intention-to-treat), substantially exceeding semaglutide monotherapy. But the head-to-head story is more complex: REDEFINE 4 failed to demonstrate noninferiority to tirzepatide, a result that rattled Novo Nordisk’s stock price and forced a nuanced conversation about what “close but not equivalent” means for prescribers and patients. This article examines all of it—the mechanism, the data, the competitive context, and the honest gaps.

Quick Facts: CagriSema at a Glance

What Is CagriSema?

Your pancreas doesn’t just make insulin. Every time you eat, beta cells co-release a second hormone called amylin that travels to your brainstem and tells you to stop eating. It’s the “I’m full” signal that ends a meal. The problem: natural amylin vanishes from your blood in under 10 minutes—far too fast to build a once-weekly drug around. Cagrilintide is an engineered version of amylin with three amino acid swaps and a fatty acid tail that lets it bind to albumin in the blood, stretching its half-life to about seven days. That half-life match is what makes CagriSema possible: cagrilintide lasts as long as semaglutide, so both hormones can be combined into one weekly injection.

CagriSema is therefore a co-formulated, fixed-dose combination of cagrilintide (2.4 mg) and semaglutide (2.4 mg) in a single prefilled pen. It is not two separate injections. It is not a single molecule that hits multiple receptors (like tirzepatide, which is one peptide targeting both GLP-1R and GIPR). CagriSema is two distinct peptide analogs, targeting two distinct receptor families, delivered together. The distinction matters pharmacologically: tirzepatide’s dual agonism is built into its molecular structure, while CagriSema’s dual mechanism is a formulation strategy combining two independent drugs.

Origins and Rationale

The rationale for pairing amylin with GLP-1 agonism predates CagriSema by over a decade. Preclinical research consistently showed that amylin and GLP-1 produce additive appetite suppression in rodent models—unsurprising, given that the two hormones act at anatomically distinct brain regions (amylin at the area postrema and nucleus tractus solitarius; GLP-1 at the hypothalamus and brainstem reward circuits) via distinct receptor families. Early clinical work with pramlintide (the only previously approved amylin analog) combined with liraglutide confirmed promising weight loss signals in humans. But pramlintide’s fatal flaw was pharmacokinetic: its half-life of approximately 50 minutes required three daily injections with meals, making it pharmacokinetically incompatible with once-weekly GLP-1 agonists.

Novo Nordisk’s development of cagrilintide solved this problem by engineering a long-acting amylin analog with a ~7-day half-life deliberately matched to semaglutide. Cagrilintide was built on the human amylin backbone with three key modifications: N14E and V17R substitutions that create a salt bridge stabilizing the central helix, P37Y for improved receptor binding, and N-terminal lipidation (a fatty acid chain) for reversible albumin binding—the same pharmacokinetic strategy that gives semaglutide its extended half-life. The Phase II dose-finding trial for cagrilintide monotherapy (published in The Lancet, 2021; PMID: 34798060) established dose-dependent weight loss, with the 4.5 mg dose outperforming liraglutide 3.0 mg. The Phase II combination trial in T2D (The Lancet, 2023; PMID: 37364590) then confirmed the additive hypothesis: CagriSema produced 15.6% weight loss at 32 weeks versus 5.1% for semaglutide alone—a signal strong enough to trigger the Phase III REDEFINE program.

The broader strategic context is Eli Lilly’s tirzepatide. When SURMOUNT-1 reported ~22% weight loss and SURMOUNT-5 confirmed tirzepatide’s superiority over semaglutide in a head-to-head trial, Novo Nordisk needed an answer. CagriSema is that answer. Rather than developing a me-too dual GLP-1/GIP agonist, Novo Nordisk bet on a fundamentally different second mechanism—amylin receptor agonism—combined with their market-leading GLP-1 component.

Mechanism of Action

Semaglutide Component (GLP-1 Receptor)

The semaglutide component functions identically to semaglutide monotherapy (Wegovy/Ozempic). GLP-1 receptor activation in the hypothalamus and brainstem produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and—most relevant to the weight loss indication—central appetite suppression. The appetite effects operate primarily between meals: reduced food cravings, decreased reward-driven eating, and lower overall caloric intake. GLP-1R agonism also improves hepatic insulin sensitivity and has demonstrated cardiovascular benefit in the SELECT trial (semaglutide monotherapy, PMID: 37952131).

Cagrilintide Component (Amylin Receptors AMY1-3)

Cagrilintide activates amylin receptors (AMY1R, AMY2R, AMY3R), which are heterodimers of the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3). These receptors are expressed primarily in the area postrema and nucleus tractus solitarius—brainstem regions that integrate meal-related satiety signals arriving from the gastrointestinal tract via the vagus nerve.

The key mechanistic contribution of amylin receptor agonism is acute meal-time satiety: cagrilintide signals meal termination, reducing meal size by accelerating the point at which a person feels full during a meal. This is temporally and neuroanatomically distinct from GLP-1’s between-meal appetite suppression. A 2025 study in eBioMedicine confirmed that cagrilintide’s weight-lowering effect depends specifically on AMY1R and AMY3R—knocking out either receptor in mice abolished the drug’s efficacy.

Why the Combination Produces More Than Either Component Alone

The combination is complementary rather than redundant. This is not a trivial distinction. Tirzepatide’s dual GLP-1/GIP agonism has faced legitimate questions about whether GIPR agonism adds a separate mechanism or merely amplifies GLP-1 signaling through overlapping pathways. With CagriSema, the complementarity is unambiguous: different peptides, different receptors, different neural circuits, different temporal profiles of action. REDEFINE 1 provided direct evidence—the combination produced approximately 10 additional percentage points of weight loss beyond semaglutide monotherapy within the same trial, a result consistent with additive rather than merely amplified effects.

The temporal complementarity is particularly elegant. Amylin receptor activation produces its primary effect at meal time (minutes to hours), reducing the quantity consumed at each eating occasion. GLP-1 receptor activation produces sustained inter-meal appetite suppression (hours to days), reducing the frequency and urgency of food-seeking behavior. Together, they address both sides of the energy intake equation: how much you eat per sitting and how often you seek food between sittings.

The Tirzepatide Question

This is the section that will age. Every other section of this article describes CagriSema in terms of its own mechanism and data. This section places it in the competitive landscape that will define its clinical and commercial trajectory—and that landscape is dominated by a single question: how does CagriSema compare to tirzepatide?

The honest answer, as of early 2026, is that CagriSema does not beat tirzepatide. REDEFINE 4, an 84-week open-label head-to-head trial in 809 adults with obesity, produced the definitive comparison: CagriSema achieved 20.2% weight loss versus tirzepatide’s 23.6% (treatment-regimen estimand), or 23.0% versus 25.5% (trial-product estimand). More importantly, CagriSema failed to meet the prespecified noninferiority margin—a statistical threshold that would have allowed Novo Nordisk to market the drug as “at least as effective.” The failure sent Novo Nordisk shares down 15% in a single day.

But the clinical picture is more nuanced than the stock market reaction. A 20% weight loss is not a failure in any absolute sense—it exceeds every GLP-1 monotherapy on the market. The noninferiority failure means CagriSema and tirzepatide are not interchangeable from a regulatory perspective. It does not mean CagriSema is clinically inadequate. For a prescriber choosing between the two, the decision will likely come down to patient-specific factors—tolerability, glucose response (CagriSema’s HbA1c reduction in REDEFINE 2 was significant), cardiovascular outcomes data (pending from REDEFINE 3), formulary access, and individual patient response.

Novo Nordisk has signaled they are not conceding. A higher-dose CagriSema trial is planned for initiation in H2 2026, and REDEFINE 11 (a full weight-loss potential study) is expected to report in H1 2027. The competitive dynamics between amylin + GLP-1 combination therapy and GLP-1/GIP dual agonism will continue to evolve.

Key Research Areas and Studies

REDEFINE 1 — The Pivotal Non-Diabetic Trial

REDEFINE 1 (PMID: 40544433) is the cornerstone study. Published in the New England Journal of Medicine in 2025, this Phase 3a trial randomized 3,417 adults with obesity or overweight (BMI ≥30, or ≥27 with comorbidity) and without type 2 diabetes across four arms: CagriSema (n=2,108), semaglutide 2.4 mg (n=302), cagrilintide 2.4 mg (n=302), and placebo (n=705). Duration: 68 weeks.

The primary endpoint, using the treatment-policy estimand (intention-to-treat, which reflects real-world adherence including dropouts), was −20.4% body weight with CagriSema versus −3.0% with placebo—a difference of 17.3 percentage points. The trial-product estimand (on-treatment, assuming all patients adhered) was approximately −22.7%. Both estimands are valid, but the ITT figure is the more conservative and clinically relevant number because it accounts for the reality that not all patients remain on treatment.

The active comparator arms are what make REDEFINE 1 uniquely informative: the combination outperformed both of its own components given separately. This within-trial monotherapy comparison—rather than the cross-trial comparisons that plagued earlier analyses—provides clean evidence that cagrilintide adds approximately 10 percentage points of weight loss beyond semaglutide alone.

Among on-treatment patients, 60% achieved ≥20% weight loss and 23% achieved ≥30%—thresholds that approach the results typically associated with bariatric surgery.

REDEFINE 2 — Type 2 Diabetes Population

REDEFINE 2 (PMID: 40544432), also published in NEJM in 2025, tested CagriSema in 1,206 adults with type 2 diabetes and overweight/obesity (HbA1c 7–10%). The trial randomized 3:1 to CagriSema or placebo over 68 weeks.

Weight loss was −13.7% with CagriSema versus −3.4% with placebo (treatment-policy estimand). The lower absolute weight loss compared to REDEFINE 1 is expected—patients with T2D consistently lose less weight on GLP-1-based therapies than patients without diabetes, a pattern observed across all drugs in this class. The glycemic result was striking: 73.5% of CagriSema patients achieved HbA1c ≤6.5% versus 15.9% with placebo, suggesting CagriSema’s dual mechanism may offer particular value in patients where both weight and glycemic control are treatment goals.

REDEFINE 4 — Head-to-Head vs. Tirzepatide

REDEFINE 4 is the trial the market cared about most. An 84-week, open-label, head-to-head Phase III comparison in 809 adults with obesity and at least one comorbidity (mean baseline weight: 114.2 kg). CagriSema 2.4/2.4 mg versus tirzepatide 15 mg, both subcutaneous once weekly.

Results (treatment-regimen estimand): CagriSema −20.2% versus tirzepatide −23.6%. Trial-product estimand: CagriSema −23.0% versus tirzepatide −25.5%. The primary endpoint of noninferiority was not met. Open-label design introduces potential bias—patients and investigators knew which drug they were receiving—but the magnitude of the difference (~3.4 percentage points) was consistent across both estimands.

Phase II Foundation

The Phase II combination trial in T2D (PMID: 37364590; Lancet, 2023) was the proof-of-concept that launched the REDEFINE program: −15.6% weight loss with CagriSema versus −5.1% with semaglutide alone over 32 weeks. The Phase II cagrilintide monotherapy dose-finding trial (PMID: 34798060; Lancet, 2021) established cagrilintide’s standalone signal: dose-dependent weight loss across 0.3–4.5 mg doses, with the highest dose outperforming liraglutide 3.0 mg.

Ongoing Trials

REDEFINE 3 (NCT05394519): Event-driven cardiovascular outcomes trial in approximately 7,000 patients with established CVD. This is the trial that will determine whether CagriSema replicates semaglutide’s MACE reduction (demonstrated in SELECT). CVOT data is increasingly required for full commercial payer coverage.

REDEFINE 5 (East Asia, 330 patients), REDEFINE 6 (China, 300 patients), REDEFINE 11 (full weight-loss potential), and a planned higher-dose trial (initiation H2 2026) round out the program.

Claims vs. Evidence

Claim	What the Evidence Shows	Verdict
CagriSema produces ~20–23% weight loss	REDEFINE 1 (N=3,417): −20.4% (ITT) to −22.7% (on-treatment) at 68 weeks vs. −3.0% placebo. Both estimands from the same NEJM-published Phase III trial.	Phase III Supported — Multiple Large RCTs
CagriSema is more effective than semaglutide alone	REDEFINE 1 included a semaglutide 2.4 mg monotherapy arm. The combination outperformed semaglutide by approximately 10 percentage points within the same trial—not a cross-trial comparison.	Phase III Supported — Within-Trial Comparison
The amylin mechanism is complementary to GLP-1	Amylin acts at AMY1-3 receptors in the brainstem (meal-time satiety); GLP-1 acts at GLP-1R in the hypothalamus (inter-meal appetite). Different peptides, receptors, circuits, and temporal profiles. Confirmed by 2025 eBioMedicine study.	Mechanistically and Clinically Supported
CagriSema is as effective as tirzepatide	REDEFINE 4 head-to-head: CagriSema −20.2% vs. tirzepatide −23.6% at 84 weeks. Noninferiority NOT met. CagriSema was numerically inferior across both estimands.	Not Supported — Tirzepatide Superior
CagriSema is superior to tirzepatide	No data support superiority. REDEFINE 4 showed tirzepatide outperformed CagriSema by ~3.4 percentage points.	Not Supported — No Superiority Data
CagriSema is a “quadruple agonist”	Completely incorrect. CagriSema targets two receptor systems: GLP-1R (semaglutide) and AMY1-3 (cagrilintide). Zero activity at GIP or glucagon receptors. Confusion with retatrutide’s triple-agonist structure.	Incorrect — Factual Error
Adding amylin is better than increasing semaglutide dose	Pharmacologically plausible: amylin activates receptors not saturable by higher semaglutide doses. However, no trial has directly compared higher-dose semaglutide to CagriSema 2.4/2.4 mg.	Plausible but Not Directly Tested
CagriSema will be approved by the FDA	NDA submitted December 18, 2025 based on REDEFINE 1 and 2 (both met primary endpoints). Approval considered likely. REDEFINE 4 noninferiority failure not expected to block placebo-controlled NDA.	Likely but Not Certain
CagriSema is available for purchase	As of April 2026, CagriSema is not commercially available. Accessible only through clinical trials. Not available from compounding pharmacies, online vendors, or any legitimate commercial source.	Not Available — Clinical Trials Only
CagriSema’s side effects are worse than semaglutide alone	REDEFINE 1: GI events in 72.5–79.6% of CagriSema vs. 34–40% placebo. These rates are numerically similar to semaglutide monotherapy. The amylin component did not substantially worsen tolerability.	Not Supported — Comparable to Semaglutide
CagriSema works for type 2 diabetes, not just weight loss	REDEFINE 2: weight loss −13.7% and 73.5% reached HbA1c ≤6.5% vs. 15.9% placebo in T2D patients. Dual mechanism well-suited to both obesity and diabetes.	Phase III Supported — Dual Benefit
CagriSema is Novo Nordisk’s “answer to tirzepatide”	Strategically accurate. Developed to recapture competitive ground. But REDEFINE 4’s noninferiority failure means the answer has not fully closed the gap. Higher-dose trial planned H2 2026.	Strategically Accurate, Clinically Incomplete

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

CagriSema is in the rare position of having more human evidence than most compounds covered on Peptidings. Three published Phase III RCTs, a Phase II combination trial, and a Phase II monotherapy trial for the cagrilintide component collectively represent data from over 6,000 patients. The quality of this evidence is high: REDEFINE 1 and 2 are large, multicenter, double-blind, placebo-controlled trials published in the New England Journal of Medicine—the gold standard for clinical evidence in medicine.

What remains unresolved is important. Cardiovascular outcomes data (REDEFINE 3) is still pending, and CV benefit—not just weight loss—is increasingly the metric that drives payer coverage and clinical adoption. Long-term safety beyond 84 weeks is not yet characterized. The weight maintenance question—what happens when patients stop CagriSema—is also unanswered, though data from semaglutide monotherapy trials suggest substantial weight regain upon discontinuation (a class-wide problem, not CagriSema-specific).

The estimand question deserves emphasis. REDEFINE 1 reported two weight loss figures: 20.4% (treatment-policy/ITT, the more conservative figure reflecting real-world adherence) and 22.7% (trial-product, reflecting outcomes in patients who stayed on treatment). Media coverage, Novo Nordisk press releases, and some clinical summaries preferentially cite the larger number. Peptidings uses the treatment-policy estimand as primary because it better represents what a population of patients will actually experience—including those who discontinue due to side effects or other reasons.

Safety, Risks, and Limitations

Gastrointestinal Effects

The dominant adverse event profile is gastrointestinal: nausea, vomiting, diarrhea, and constipation. In REDEFINE 1, GI events occurred in approximately 72–80% of CagriSema patients versus 34–40% in placebo. The vast majority were transient (resolving during the 16-week dose titration period) and graded as mild to moderate. This profile is consistent with the semaglutide component and was not meaningfully worsened by the addition of cagrilintide. The titration schedule—starting at 0.25/0.25 mg and escalating over 16 weeks to the full 2.4/2.4 mg maintenance dose—exists specifically to mitigate GI onset.

GLP-1 Class Warnings

Pancreatitis: Acute pancreatitis has been observed with GLP-1 receptor agonists, including semaglutide. REDEFINE trials did not report a statistically significant increase, but the risk is considered a class effect requiring monitoring.

Thyroid C-cell tumors: Semaglutide carries a boxed warning for thyroid C-cell tumor risk based on rodent models. The clinical relevance in humans is uncertain—no definitive causal link has been established—but medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN 2) are listed as contraindications.

Gallbladder disease: GLP-1 agonists increase the risk of cholelithiasis (gallstones), likely related to rapid weight loss rather than a direct drug effect. Semaglutide trials have shown a >2.5-fold increase in gallbladder-related events.

Hypoglycemia: Risk is low when CagriSema is not combined with insulin or sulfonylureas, because both GLP-1R and amylin receptor effects on insulin secretion are glucose-dependent. When combined with insulin or sulfonylureas, dose adjustment of those drugs is required.

Amylin-Specific Considerations

Pramlintide (Symlin), the previously approved amylin analog, carried warnings for severe hypoglycemia when combined with insulin—a pharmacological concern unique to amylin agonism. Cagrilintide’s combination with semaglutide (rather than insulin) and the absence of a severe hypoglycemia signal in REDEFINE data suggest this risk is lower in the CagriSema context. However, long-term data in patients on concurrent insulin therapy is limited.

Injection site reactions were more common with cagrilintide monotherapy in Phase II than with semaglutide alone, likely related to the amylin component.

What We Don’t Know

• Cardiovascular outcomes: REDEFINE 3 is ongoing. Whether cagrilintide preserves, enhances, or neutralizes semaglutide’s MACE reduction is unknown.
• Long-term safety beyond 84 weeks. No trial has followed CagriSema patients beyond the 84-week REDEFINE 4 duration.
• Weight regain after discontinuation. Semaglutide monotherapy trials show ~67% weight regain one year after stopping. CagriSema-specific data not yet available.
• Drug interactions: Formal drug interaction studies have not been widely published for the cagrilintide component.

Legal and Regulatory Status

FDA Status

CagriSema is not FDA-approved as of April 2026. Novo Nordisk submitted a New Drug Application (NDA) to the FDA on December 18, 2025, based on the REDEFINE 1 and REDEFINE 2 pivotal trials. The PDUFA target date (FDA decision deadline) has not been publicly disclosed but is anticipated in late 2026.

If approved, CagriSema would be the first co-formulated amylin + GLP-1 combination product on the market. The approval would cover obesity and weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidities).

The REDEFINE 4 noninferiority failure versus tirzepatide is not expected to impact the approval decision, because the NDA is based on placebo-controlled efficacy data (REDEFINE 1 and 2), not comparative effectiveness against another active drug.

WADA Status

Prohibited. The semaglutide component of CagriSema falls under WADA Prohibited List S4 (Hormone and Metabolic Modulators). Any product containing semaglutide is prohibited in competition and out-of-competition for athletes subject to WADA testing. Cagrilintide, as a pharmacological substance not approved by any regulatory health authority, would additionally be captured under S0 (“Non-Approved Substances”).

Compounding Pharmacy Availability

CagriSema is not available through compounding pharmacies. It is a proprietary Novo Nordisk formulation available only through registered clinical trial sites. Semaglutide alone has FDA-approved branded formulations (Ozempic, Wegovy, Rybelsus). Cagrilintide is not available as a standalone commercial or compounded product.

International Regulatory Landscape

No international regulatory submissions have been publicly announced beyond the US FDA NDA. European (EMA), UK (MHRA), and other submissions are expected to follow the FDA submission timeline.

Dosing in Published Research

Clinical Trial Dosing

Trial	Target Dose	Titration	Duration	Population
REDEFINE 1	Cagrilintide 2.4 mg + Semaglutide 2.4 mg	16-week escalation from 0.25/0.25 mg	68 weeks	Adults with obesity, no T2D
REDEFINE 2	Cagrilintide 2.4 mg + Semaglutide 2.4 mg	16-week escalation from 0.25/0.25 mg	68 weeks	Adults with T2D + overweight/obesity
REDEFINE 4	Cagrilintide 2.4 mg + Semaglutide 2.4 mg	16-week escalation	84 weeks	Adults with obesity + comorbidity
Phase II combo	Cagrilintide 2.4 mg + Semaglutide 2.4 mg	Escalated over study period	32 weeks	Adults with T2D
Phase II mono (cagrilintide)	0.3, 0.6, 1.2, 2.4, or 4.5 mg	Dose-finding	26 weeks	Adults with obesity, no T2D

Titration Protocol

CagriSema’s titration follows the same principle as semaglutide monotherapy: both components are escalated together over 16 weeks from a low starting dose (0.25/0.25 mg) to the full maintenance dose (2.4/2.4 mg). The slow escalation exists to mitigate GI adverse events, which are most common during the dose-increase phase. In REDEFINE trials, nausea peaked during weeks 4–8 and declined progressively thereafter.

Frequently Asked Questions

Related Compounds

CagriSema occupies a unique position in the Cluster A landscape. It is the only combination product—two distinct peptide analogs in a single injection—rather than a single multi-target molecule. This distinction matters because it affects manufacturing complexity, dosing flexibility (both components are locked at a fixed ratio), and the regulatory pathway (each component has its own safety and efficacy contribution to justify).

Direct Competitors

Tirzepatide (GLP-1R/GIPR dual agonist, FDA-approved, ~22% weight loss) is the primary competitive benchmark. Retatrutide (GLP-1R/GIPR/GcgR triple agonist, Phase III, ~24% Phase II weight loss) represents the next-generation threat. Survodutide (GLP-1R/GcgR dual agonist, Phase III) is also in this tier.

The Market Leader CagriSema Aims to Complement

Semaglutide (Wegovy/Ozempic, FDA-approved, ~15% weight loss) is both CagriSema’s baseline and its included component. The entire value proposition of CagriSema rests on the ~10 percentage points of additional weight loss cagrilintide adds to semaglutide.

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Weight Loss Efficacy	Route	Mechanism Class	Key Differentiator
Semaglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~7 days	FDA-approved (Wegovy, Ozempic)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III)	Subcutaneous injection (weekly)	GLP-1 agonist	Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding
Tirzepatide	Synthetic dual GLP-1R/GIPR agonist peptide	GLP-1R / GIPR	~5 days	FDA-approved (Zepbound, Mounjaro)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III SURMOUNT-3)	Subcutaneous injection (weekly)	Dual GLP-1/GIP agonist	Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism
Retatrutide	Synthetic triple GLP-1R/GIPR/GcgR agonist peptide	GLP-1R / GIPR / GcgR	~5 days	Phase III clinical trials (not yet approved)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 24% body weight reduction (Phase II)	Subcutaneous injection (weekly)	Triple GLP-1/GIP/glucagon agonist	Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression
Liraglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~13 hours	FDA-approved (Saxenda, Victoza)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 8% body weight reduction (Phase III SCALE)	Subcutaneous injection (daily)	GLP-1 agonist	First GLP-1 RA approved for weight management. Daily dosing. Well-established long-term safety data
Orforglipron	Non-peptide small-molecule GLP-1 receptor agonist	GLP-1R	~11 hours	FDA-approved (Foundayo)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 15% body weight reduction (Phase II interim)	Oral (small molecule)	GLP-1 agonist (oral)	First oral non-peptide GLP-1 RA approved for weight management. Room-temperature stable, no injection required
CagriSema	Synthetic fixed-ratio combination (semaglutide + cagrilintide)	GLP-1R / AmylinR	~7 days (semaglutide) / ~7 days (cagrilintide)	Phase III clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 20% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/amylin dual agonist	Combines GLP-1 RA with long-acting amylin analog. Amylin pathway targets satiety and gastric emptying synergistically
Survodutide	Synthetic dual GLP-1R/GcgR agonist peptide	GLP-1R / GcgR	~3–4 days	Phase II clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase II)	Up to 18% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/glucagon dual agonist	Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists
AOD-9604	Modified fragment of GH (amino acids 177–191)	GH mimetic (fragment-based)	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — as GH fragment	Tier 3 — Pilot / Limited Human Data	~2–3% body weight reduction (limited human data)	Subcutaneous injection	GH C-terminus analog (lipolytic)	Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims
5-Amino-1MQ	Synthetic small molecule quinone metabolite analog	NNMT inhibitor	~6–8 hours	Not FDA-approved	Not WADA-listed — emerging research compound	Tier 4 — Preclinical Only	~5–8% body weight reduction (mouse models only; limited human data)	Oral (small molecule)	NNMT inhibition (NAD+ pathway)	Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published
MOTS-c	Synthetic mitochondrial open-reading-frame peptide (13 amino acids)	AMPK activator (AMP-kinase pathway)	~2–4 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 4 — Preclinical Only	Modest weight reduction (animal models); no published human trials	Subcutaneous injection	Mitochondrial-derived peptide analog	Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published
Tesamorelin	Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification)	GHRH-R	~26 minutes	FDA-approved (Egrifta for lipodystrophy in HIV)	Prohibited — S2 (GHRH analog)	Tier 1 — Approved Drug	~2–4% visceral fat reduction (HIV lipodystrophy indication)	Subcutaneous injection (daily)	GHRH analog	Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations

Summary and Key Takeaways

CagriSema is the strongest unapproved obesity drug in the regulatory pipeline. Phase III data from REDEFINE 1 (N=3,417) demonstrated 20.4% weight loss at 68 weeks—roughly twice what semaglutide monotherapy achieves—and the NDA is under FDA review with a decision expected late 2026.

The amylin + GLP-1 combination is pharmacologically elegant and clinically validated. Unlike receptor-redundant “stacking” approaches, CagriSema’s dual mechanism targets distinct satiety pathways: amylin for meal-time fullness, GLP-1 for inter-meal appetite suppression. REDEFINE 1’s within-trial superiority over each monotherapy arm provides clean evidence of additive effect.

CagriSema does not beat tirzepatide. REDEFINE 4’s head-to-head comparison (20.2% vs. 23.6% weight loss; noninferiority not met) means prescribers and patients should not consider the two drugs interchangeable. Tirzepatide’s GLP-1R/GIPR dual agonism produced numerically superior weight loss. This does not diminish CagriSema’s absolute efficacy—it contextualizes it.

The gaps are important but not disqualifying. Cardiovascular outcomes data (REDEFINE 3) is pending. Long-term safety beyond 84 weeks is uncharacterized. Weight regain after discontinuation is expected to mirror semaglutide monotherapy’s pattern. These are the questions a well-informed patient and prescriber need answered before CagriSema’s place in the treatment landscape crystallizes.

Plain English Scorecard

Question	Answer
What is it?	Two appetite-suppressing drugs (semaglutide + cagrilintide) in a single once-weekly injection
Does it work?	Yes—20% weight loss in the largest trial, roughly double semaglutide alone
Is it better than tirzepatide?	No—the head-to-head trial showed tirzepatide produced about 3% more weight loss
Is it safe?	Similar side effects to semaglutide alone—mainly GI issues during dose escalation
Can I get it?	Not yet—only available through clinical trials. NDA under FDA review, decision expected late 2026
Is it banned in sports?	Yes—the semaglutide component is WADA-prohibited

Verdict Recapitulation

Three published Phase III RCTs in NEJM, NDA under FDA review, head-to-head data versus tirzepatide. CagriSema’s dual-mechanism approach—amylin for meal-time satiety, GLP-1 for inter-meal appetite suppression—is pharmacologically validated and clinically meaningful. Tier 1 pending approval.

Where to Source CagriSema

Further Reading and Resources

If you want to go deeper on CagriSema, the evidence landscape for weight loss and metabolic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• Semaglutide — The GLP-1 agonist that forms half of CagriSema
• Tirzepatide — The dual GLP-1/GIP agonist CagriSema was tested against
• Retatrutide — Eli Lilly’s triple agonist (GLP-1/GIP/glucagon)
• Liraglutide — First-generation daily GLP-1 agonist
• Survodutide — GLP-1/glucagon dual agonist in Phase III
• Weight Loss & Metabolic Research Cluster Hub — All compounds in this category
• Evidence Levels Explained — How Peptidings assigns evidence tiers
• Half-Lives and Dosing Intervals — Why cagrilintide’s 7-day half-life matters
• Accessing GLP-1 Medications — Legitimate pathways for GLP-1 drugs
• How to Read a Research Study — Understanding clinical trial data

External Resources

• PubMed — Biomedical Research Database — Search for “CagriSema” or “cagrilintide semaglutide”
• ClinicalTrials.gov — Check for registered REDEFINE trials and enrollment status

Selected References and Key Studies

1. Garvey WT, et al., “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2025. PMID: 40544433 PubMed
2. Davies MJ, et al., “Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.” New England Journal of Medicine, 2025. PMID: 40544432 PubMed
3. REDEFINE 4 investigators. CagriSema demonstrated 23% weight loss in open-label head-to-head trial versus tirzepatide; primary endpoint not achieved. Novo Nordisk company announcement, December 2024.
4. Frias JP, et al., “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes.” The Lancet, 2023;402:720–730. PMID: 37364590 PubMed
5. Lau DCW, et al., “Once-weekly cagrilintide for weight management in people with overweight and obesity.” The Lancet, 2021;398:2160–2172. PMID: 34798060 PubMed
6. Mathiesen DS, et al., “Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.” Cardiology in Review, 2024;32(1):97–102. PMID: 36883831 PubMed
7. “Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.” eBioMedicine (The Lancet), 2025.
8. “Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.” Nature Communications, 2025.
9. Lincoff AM, et al., “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 2023;389:2221–2232. PMID: 37952131 PubMed
10. ClinicalTrials.gov. “A Research Study to See How Well CagriSema Works in People Who Have Obesity and Established Cardiovascular Disease (CVD) (REDEFINE 3).” NCT05394519.
11. Novo Nordisk. “Novo Nordisk files for FDA approval of CagriSema.” Press release, December 18, 2025.
12. “Amylin as a Future Obesity Treatment.” Journal of Clinical Medicine, 2022;11(1):186. PMC: 8735818